For years, allogeneic CAR T cell therapy carried one of the field’s biggest promises: cancer-fighting cells made from healthy donors, stocked in advance, and ready the moment a patient needed them. Caribou Biosciences built its pipeline around that vision, using CRISPR genome editing to engineer donor cells that could persist and fight tumors. On October 6th, the company announced it would shelve both of its allogeneic chimeric antigen receptor (CAR) T cell therapy programs, including one ready for a Phase 3 trial.
The decision came down to money. The company, cofounded by Nobel laureate Jennifer Doudna, said it will make substantial cuts to its workforce and explore strategic alternatives, including a merger, acquisition, or sale of its assets.
“The current financing environment for allogeneic CAR-T cell therapies has made it increasingly challenging to secure the capital necessary to responsibly advance these programs,” said Rachel Haurwitz, President and CEO of Caribou, in a statement.
Caribou reported $113.8 million in cash, cash equivalents, and marketable securities as of June 30th, 2026, and expects the workforce reduction to be mostly complete by the end of the year. Its exit lands at a moment when investor money is flowing toward a rival approach that promises the same off-the-shelf convenience by programming T cells inside the patient’s body.
Two engineered programs reach a stopping point
Both discontinued therapies used genome editing to address the core weaknesses of donor-derived CAR T cells. The lymphoma program, an anti-CD19 therapy for relapsed or refractory B-cell non-Hodgkin lymphoma, carried a PD-1 knockout designed to limit premature T cell exhaustion. According to Caribou, it was ready for a pivotal trial, with FDA alignment already reached on the Phase 3 design. The company has also said the therapy showed safety, efficacy, and durability comparable to autologous CAR T products.
The myeloma program targeted B-cell maturation antigen in relapsed or refractory multiple myeloma. Its cells carried a B2M knockout paired with an inserted B2M–HLA-E peptide fusion protein, an immune cloaking strategy meant to blunt rejection by the patient’s immune system. Both programs held regenerative medicine advanced therapy, Fast Track, and Orphan Drug designations from the FDA.
Why off-the-shelf cell therapy is a harder sell
Allogeneic CAR T therapies promised to solve the biggest logistical problems of the autologous products on the market today. Because they are made from healthy donor cells in advance, they could be stored and given to patients immediately at lower cost per dose. In practice, developers have had to engineer around host rejection, which shortens how long the cells persist and raises questions about durability compared with a patient’s own cells.
The regulatory bar has also risen. Late last year, FDA officials shared a stricter framework requiring new cancer CAR T therapies to show a survival or event-free benefit in randomized controlled trials, with control arms that account for approved CAR T products. For a company with roughly $114 million in the bank, a head-to-head Phase 3 against established autologous therapies is a steep climb.
Capital moves toward in vivo approaches
Meanwhile, investment has flowed to in vivo CAR T, which programs T cells inside the patient and skips cell manufacturing altogether, delivering the same off-the-shelf convenience allogeneic therapies aimed for. Eli Lilly announced plans in April to acquire in vivo developer Kelonia Therapeutics for $7 billion, and in August Johnson & Johnson struck a deal with Sail Biomedicines worth more than $3.5 billion to develop in vivo CAR T therapies for immune-mediated diseases.
Early clinical data have reinforced that momentum. At the International Myeloma Society meeting in late September, IASO Bio reported that nine of 10 patients with relapsed or refractory multiple myeloma responded to a single infusion of its in vivo BCMA CAR T therapy, given without lymphodepleting chemotherapy. The results are early and come from a small Phase 1 study.
What it means for drug developers
For teams building allogeneic cell therapies, Caribou’s decision signals that investors now expect clear evidence of durability and differentiation before committing late-stage capital, especially with randomized trials now part of the regulatory path. For the wider field, the engineering behind Caribou’s programs, from checkpoint knockouts to immune cloaking, remains relevant to next-generation cell therapies, and the strategic review could place these assets with a company better positioned to run a pivotal trial.
The broader lesson is about where the field is placing its bets. Off-the-shelf access remains the goal, and right now, investors are backing approaches that reach it by eliminating cell manufacturing entirely.
